# Hannelore Denys

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/hannelore-denys/

## Facts

| Field | Value |
| --- | --- |
| Citations | 8,911 |
| Field | Ovarian cancer diagnosis and treatment |
| h-index | 43 |
| i10-index | 100 |
| Last Known Institution | Ghent University Hospital |
| OpenAlex ID | https://openalex.org/A5008683883 |
| ORCID iD | 0000-0002-8897-9430 |
| Works | 338 |

## Researcher papers

- [Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial](https://scholariq.org/papers/rucaparib-maintenance-treatment-for-recurrent-ovarian-carcinoma-after-response/)
- [Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study](https://scholariq.org/papers/efficacy-and-safety-of-tisotumab-vedotin-in-previously-treated-recurrent-or/)
- [Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study](https://scholariq.org/papers/efficacy-and-safety-of-mirvetuximab-soravtansine-in-patients-with-platinum/)
- [Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial](https://scholariq.org/papers/durvalumab-plus-carboplatin-paclitaxel-followed-by-maintenance-durvalumab-with/)
- [Increased levels of systemic LPS-positive bacterial extracellular vesicles in patients with intestinal barrier dysfunction](https://scholariq.org/papers/increased-levels-of-systemic-lps-positive-bacterial-extracellular-vesicles-in/)
- [Confounding factors of ultrafiltration and protein analysis in extracellular vesicle research](https://scholariq.org/papers/confounding-factors-of-ultrafiltration-and-protein-analysis-in-extracellular/)
- [The Role of Epithelial-to-Mesenchymal Plasticity in Ovarian Cancer Progression and Therapy Resistance](https://scholariq.org/papers/the-role-of-epithelial-to-mesenchymal-plasticity-in-ovarian-cancer-progression/)
- [Effect of the Secretory Small GTPase Rab27B on Breast Cancer Growth, Invasion, and Metastasis](https://scholariq.org/papers/effect-of-the-secretory-small-gtpase-rab27b-on-breast-cancer-growth-invasion-and/)
- [Strain Rate Imaging Detects Early Cardiac Effects of Pegylated Liposomal Doxorubicin as Adjuvant Therapy in Elderly Patients with Breast Cancer](https://scholariq.org/papers/strain-rate-imaging-detects-early-cardiac-effects-of-pegylated-liposomal/)
- [Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression through paracrine neuregulin 1/HER3 signalling](https://scholariq.org/papers/bone-marrow-derived-mesenchymal-stem-cells-promote-colorectal-cancer-progression/)
- [Efficacy and safety of niraparib in patients aged 65 years and older with advanced ovarian cancer: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial](https://scholariq.org/papers/efficacy-and-safety-of-niraparib-in-patients-aged-65-years-and-older-with/)

## Researcher topics

- [Ovarian cancer diagnosis and treatment](https://scholariq.org/topics/ovarian-cancer-diagnosis-and-treatment/)
- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Endometrial and Cervical Cancer Treatments](https://scholariq.org/topics/endometrial-and-cervical-cancer-treatments/)
- [PARP inhibition in cancer therapy](https://scholariq.org/topics/parp-inhibition-in-cancer-therapy/)
- [Advanced Breast Cancer Therapies](https://scholariq.org/topics/advanced-breast-cancer-therapies/)

## Researcher university

- [Ghent University Hospital](https://scholariq.org/institutions/ghent-university-hospital/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.